GCG and type 2 diabetes mellitus: To the authors’ knowledge, no other studies of ASBT inhibition in patients with T2DM have been published, although a study of elobixibat in patients with chronic constipation reported that increases in peak GLP-1 levels, but not morning basal or total AUC levels, on day 12 were greater in the active treatment groups (elobixibat 15 mg and 20 mg once daily) than in the placebo group [39].